Clinical Trials in Maryland

Showing 2221-2240 of 11,119 trials

Device Feasibility and Acceptability to Improve Insomnia in Cancer

NCT05875129

Sleep disruption is common among young adult cancer survivors for a variety of reasons. Cognitive behavioral therapy for insomnia (CBT-I) has been shown to improve chronic sleep disorders. This project will test the feasibility and acceptability of a new voice-activated virtual assistant (VAVA) device to deliver CBT-I to improve sleep among young adult cancer survivors with chronic sleep disorders.

CancerInsomnia Chronic

Medstar Health Research Institute15 participantsStarted Jul 2022

Washington D.C., District of Columbia, United States

COMPLETEDPhase 217 miles

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

NCT04669600

Primary Objective: \- To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP) Secondary Objectives: * To assess the safety and tolerability of BIVV020 * To assess the pharmacokinetics of BIVV020 * To assess the response rate of treatment with BIVV020 * To assess the time to response * To assess the effect of treatment with BIVV020 on the requirement for rescue ITP therapy * To assess the immunogenicity of BIVV020

Immune Thrombocytopenia (ITP)

Bioverativ, a Sanofi company12 participantsStarted Feb 2021

Washington D.C., District of Columbia, United States • Tamarac, Florida, United States • Ostrava - Poruba, Czechia +6 more locations

RECRUITINGPhase 317 miles

Abatacept in Immune Checkpoint Inhibitor Myocarditis

NCT05335928

The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.

Myocarditis AcuteCancer

Massachusetts General Hospital390 participantsStarted Jul 2022

Los Angeles, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +28 more locations

Device Feasibility and Acceptability to Improve Insomnia in Cancer

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Abatacept in Immune Checkpoint Inhibitor Myocarditis

Find Trials by Condition in Maryland

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

Post-transplant Flotetuzumab for AML

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Periprosthetic Fracture Registry (PPFx)

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis